To investigate the tumor-initiating capacity of CD90+ cells in vivo, CD90+ and CD90− cells were subcutaneously implanted in Severe Combined Immunodeficiency (SCID) mice (Fig. 2C, Supplementary Table 1). The gene discussed is THY1; the disease is neoplasm.